AstraZeneca Launches Fasenra in China for Severe Asthma Treatment

AstraZeneca (AZN.US) has announced the commercial launch of its innovative biologic, Fasenra (generic name: benralizumab injection), in China. This drug is specifically designed for the maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 and above. Fasenra is a targeted biologic that precisely addresses eosinophils (EOS) by inhibiting the interleukin-5 receptor (IL-5R).

The drug has shown rapid improvement in asthma symptoms within three days of treatment in patients with a baseline blood eosinophil count (bEOS) of 300/μL or higher, as indicated by a pooled analysis study. The PONENTE and SHAMAL studies further demonstrated that over 90% of severe asthma patients reduced their use of oral corticosteroids (OCS) and inhaled corticosteroids (ICS) with fluticasone, indicating long-term safety and efficacy.

Chen Xi, Vice President of AstraZeneca China and Head of the Respiratory and Immunology, Biopharmaceuticals, Vaccines, and Immunotherapy Business Unit, expressed his enthusiasm for the launch. He highlighted that Fasenra marks a significant milestone as the first biologic in AstraZeneca's respiratory portfolio to be launched in China. This launch signifies the entry of China into the era of precision-targeted treatment for severe asthma. Currently, AstraZeneca offers a comprehensive range of products in China, covering mild to severe asthma, and providing solutions for the entire spectrum of asthma management. The company is committed to accelerating the introduction of innovative drugs to offer more personalized and precise treatment options for patients.

This development is a significant step forward in the treatment of severe eosinophilic asthma, providing patients with a more targeted and effective therapeutic option. The launch of Fasenra in China underscores AstraZeneca's commitment to advancing respiratory health and improving the quality of life for patients suffering from severe asthma. The company's focus on precision medicine and innovative biologics is expected to continue driving advancements in the field, offering new hope to patients in need of more effective treatment options.